Oxford Biomedica PLC

AGM Information • Jun 24, 2024

National Storage Mechanism | Additional information

RNS Number : 6676T

Oxford Biomedica PLC

24 June 2024

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 24 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that  all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 24 June 2024 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2024 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (20 June 2024) there were 105,268,630 ordinary shares of 50 pence each in issue, each carrying one vote per share.

	Resolution	Votes For (incl. votes at the Chairman's discretion)	% of votes cast	Votes Against	% of votes cast	Votes Withheld*	Total votes cast	Result
	Ordinary resolutions
1	To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2023, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports.	72,477,617	99.99%	4,552	0.01%	608,560	72,482,169	PASS
2	To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) for the financial year ended 31 December 2023.	72,347,034	99.61%	280,462	0.39%	463,233	72,627,496	PASS
3	To consider and, if thought fit, approve the Directors' Remuneration Policy, the full text of which is included in the Directors' Remuneration Report for the financial year ended 31 December 2023.	70,899,498	97.67%	1,691,080	2.33%	500,151	72,590,578	PASS
4	To appoint Peter Soelkner as a Director of the Company.	72,622,493	99.98%	11,817	0.02%	456,419	72,634,310	PASS
5	To reappoint Dr. Roch Doliveux as a Director of the Company.	72,614,517	99.97%	18,800	0.03%	457,412	72,633,317	PASS
6	To reappoint Stuart Henderson as a Director of the Company.	72,621,001	99.98%	13,309	0.02%	456,419	72,634,310	PASS
7	To reappoint Professor Dame Kay Davies as a Director of the Company.	72,619,922	99.98%	13,395	0.02%	457,412	72,633,317	PASS
8	To reappoint Dr. Frank Mathias as a Director of the Company.	72,623,288	99.99%	10,522	0.01%	456,919	72,633,810	PASS
9	To reappoint Stuart Paynter as a Director of the Company.	72,623,118	99.99%	10,199	0.01%	457,412	72,633,317	PASS
10	To reappoint Robert Ghenchev as a Director of the Company.	72,585,321	99.93%	47,996	0.07%	457,412	72,633,317	PASS
11	To reappoint Namrata Patel as a Director of the Company.	72,619,735	99.98%	13,582	0.02%	457,412	72,633,317	PASS
12	To reappoint Leone      Patterson as a Director of the Company.	71,427,129	98.34%	1,206,006	1.66%	457,594	72,633,135	PASS
13	To reappoint Dr. Heather Preston as a Director of the Company.	71,207,370	98.04%	1,425,964	1.96%	457,395	72,633,334	PASS
14	To appoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the meeting until the conclusion of the next AGM of the Company at which the accounts are laid.	72,579,009	99.98%	16,159	0.02%	495,561	72,595,168	PASS
15	To authorise the Audit Committee for and on behalf of the Board to determine the auditor's remuneration.	72,580,492	99.98%	15,389	0.02%	494,848	72,595,881	PASS
16	To approve the Oxford Biomedica 2024 Long Term Incentive Plan.	62,538,002	86.10%	10,095,007	13.90%	457,720	72,633,009	PASS
17	To approve the Oxford Biomedica 2024 Deferred Bonus Plan.	62,775,222	86.43%	9,856,415	13.57%	459,092	72,631,637	PASS
18	To approve the Oxford Biomedica 2024 Sharesave Scheme.	63,225,470	87.05%	9,408,593	12.95%	456,666	72,634,063	PASS
19	To authorise the Directors to allot shares.	72,168,633	99.41%	426,961	0.59%	495,135	72,595,594	PASS
20	To authorise the Directors to disapply pre-emption rights.	72,215,940	99.48%	378,341	0.52%	496,448	72,594,281	PASS
21	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.	72,215,440	99.48%	378,841	0.52%	496,448	72,594,281	PASS
22	To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.	72,369,632	99.63%	265,377	0.37%	455,720	72,635,009	PASS

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

In addition, further to the announcement by the Company on 11 March 2024, Dr. Michael Hayden and Catherine Moukheibir have stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: +44 (0)1865 783 000

ABOUT OXFORD BIOMEDICA

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com , and follow us on LinkedIn and YouTube .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGQKQBQABKDDAB